98%
921
2 minutes
20
Vascular depression (VaDep), which was proposed over two decades ago, is a distinct subtype of depression primarily observed in patients with stroke and cerebral small-vessel disease and is characterized by white matter hyperintensities; however, the lack of standardized diagnostic criteria and consensus limits its clinical application. This review explores the pathological conditions and vascular risk factors that may precipitate VaDep, particularly in relation to stroke and cerebral small-vessel disease. VaDep is distinguished by unique pathophysiological mechanisms and treatment responses. We categorize these mechanisms into three groups: 1) macroscopic mechanisms, including vascular aging, cerebral hypoperfusion, blood-brain barrier disruption, and neural circuit dysfunction; 2) microscopic mechanisms, involving the inflammatory response, hypothalamic-pituitary-adrenal axis dysregulation, impaired monoamine synthesis, and mitochondrial dysfunction; and 3) undetermined mechanisms, such as microbiota-gut-brain axis dysbiosis. These insights support VaDep as a distinct depression subtype, differentiating it from late-life depression and major depressive disorder. Treatment is challenging, as patients with VaDep often exhibit resistance to conventional antidepressants. Addressing vascular risk factors and protecting vascular integrity are essential for effective management. Future research should validate these mechanisms and develop novel diagnostic and therapeutic approaches to improve VaDep outcomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.nbd.2025.106946 | DOI Listing |
J Neuropsychiatry Clin Neurosci
September 2025
Departments of Radiology, Neurology, and Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY.
Objective: One of the most frequent neuropsychiatric complications after a stroke is poststroke depression (PSD). However, it is unclear whether disparities exist in PSD diagnosis. The authors examined a 10-year trend in PSD by socioeconomic and clinical characteristics.
View Article and Find Full Text PDFSleep
September 2025
Center for Sleep Medicine, Hospices Civils de Lyon, Lyon 1 University, Lyon, F-69000, France.
Current treatments for narcolepsy type 1 (NT1) have little impact on psychiatric, cognitive and metabolic comorbidities. Here, we evaluated the feasibility, safety and efficacy of a prospective Exercise Training (ET) program on sleep-related symptoms and comorbidities in NT1. Sedentary adult with NT1 participated in a 6-week supervised ET program followed by a 18-week self-directed program.
View Article and Find Full Text PDFFront Cardiovasc Med
August 2025
Department of Medicine, Hualien Armed Forces General Hospital, Hualien City, Taiwan.
Background: The association observed between mental stress and metabolic syndrome (MetS) has varied across studies and may be confounded by physical activity (PA) and fitness status.
Method: This study included a military cohort of 2,854 participants in Taiwan who were not taking any medications and were free of baseline MetS. The Brief Symptoms Rating Scale (BSRS-5) includes five domains-depression, anxiety, hostility, insomnia, and interpersonal sensitivity-measured on a five-point Likert-type scale ranging from 0 to 4, with a maximum score of 20.
Psychiatry Res
September 2025
School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China. Electronic address:
Objectives: To evaluate the relationship between depression and the risk of dementia.
Design: A real-world longitudinal study.
Setting: This comprehensive study involved elderly adults in Yichang, China, who were dementia-free at baseline from 2016 to 2023.
Cureus
August 2025
Service of Neurology, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, BRA.
Transcranial sonography (TCS) is widely acknowledged as a frontline imaging tool in movement disorder practice, particularly for separating idiopathic Parkinson's disease from its many mimics. In recent years, however, investigators have extended its reach, showing that the same portable probe can also capture structural and hemodynamic signatures of neuropsychiatric disorders and the major dementia syndromes. Across neuropsychiatry, a dim ("hypoechoic") median raphe emerges as the sonographic hallmark of serotonergic imbalance: it recurs in major depressive disorder, bipolar depression, and panic disorder, predicts better response to selective serotonin reuptake inhibitors, and even foreshadows post-stroke depression.
View Article and Find Full Text PDF